IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-23 DOI: 10.1002/cmdc.202500340

Xuanming Teng, Jingyi Yang, Zhiyi Ren, Sha Yan, Jiaxin Zhai, Xinyuan Hu, Shule Hou, Yangyang Yang

{"title":"Programmed Targeted Protein Degradation Via DNA Modularized Ligand.","authors":"Xuanming Teng, Jingyi Yang, Zhiyi Ren, Sha Yan, Jiaxin Zhai, Xinyuan Hu, Shule Hou, Yangyang Yang","doi":"10.1002/cmdc.202500340","DOIUrl":"https://doi.org/10.1002/cmdc.202500340","url":null,"abstract":"Proteolysis targeting chimera (PROTAC) technology holds great promise as a protein degradation modality in therapeutic development. However, there remain challenges, including complex chemical synthesis and linker screening. To address this, a proof-of-concept of a new modularized method by constructing DNA-PROTAC is presented by identifying the valid BRD4 and Sirt2 DNA-PROTACs. These findings may provide new approaches for linker design and ligand screening for PROTACs. Herein, a ligand modularization strategy is proposed that leverages the programmability of DNA to modulate the design and construction of PROTAC molecules to facilitate the programmatic discovery of new PROTAC molecules. The bromodomain-containing protein 4 (BRD4) is selected as a target for degradation to verify the effectiveness of DNA-PROTACs. The kinetics of BRD4 degradation were assessed by performing time-course experiments in HeLa cells. In addition, to evaluate the feasibility of the DNA-PROTAC strategy for degradation of other proteins, the silent mating type information regulation 2 homolog-2 (Sirt2) is selected as the degradation target. The design and synthesis procedures of BRD4 and Sirt2 DNA-PROTACs and their mechanisms of action, are systematically introduced, and the results may provide a new method for linker design and ligand screening of PROTACs.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500340"},"PeriodicalIF":3.6,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Front Cover: (ChemMedChem 14/2025) 封面：（ChemMedChem 14/2025）

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-19 DOI: 10.1002/cmdc.202581401

引用次数: 0

Estimation of In Vivo Half-Life From In Vitro Metabolic Clearance, Protein, and Cell Membrane Affinity Assays. 通过体外代谢清除率、蛋白质和细胞膜亲和力测定估算体内半衰期。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-19 DOI: 10.1002/cmdc.202500459

Carla Pou Miralbell, Sandrine Desrayaud, Berndt Oberhauser, John Reilly, Yves P Auberson

引用次数: 0

Identification of a New Interesting BAG3 Modulator Able to Disrupt Cancer-Related Pathways. 一种能够破坏癌症相关通路的新的BAG3调节剂的鉴定

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-09 DOI: 10.1002/cmdc.202500310

Dafne Ruggiero, Eleonora Boccia, Emis Ingenito, Vincenzo Vestuto, Gilda D'Urso, Alessandra Capuano, Agostino Casapullo, Stefania Terracciano, Giuseppe Bifulco, Gianluigi Lauro, Ines Bruno

引用次数: 0

Cyclin-dependent Kinase 11: Cellular Functions and Potential Therapeutic Applications. 细胞周期蛋白依赖性激酶11：细胞功能和潜在的治疗应用。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-08 DOI: 10.1002/cmdc.202500305

Janhabee Shrestha, Jason Blanchard, Solomon Tadesse

{"title":"Cyclin-dependent Kinase 11: Cellular Functions and Potential Therapeutic Applications.","authors":"Janhabee Shrestha, Jason Blanchard, Solomon Tadesse","doi":"10.1002/cmdc.202500305","DOIUrl":"https://doi.org/10.1002/cmdc.202500305","url":null,"abstract":"Cyclin-dependent kinase 11 (CDK11) is a multifunctional serine/threonine protein kinase that plays a pivotal role in transcription and pre-mRNA splicing. It phosphorylates serine 2 of RNA polymerase II C-terminal domain, thereby promoting transcriptional elongation and 3'-end processing of replication-dependent histone genes, as well as contributing to proper chromosome segregation during mitosis. CDK11 is essential for global pre-mRNA splicing by phosphorylating Splicing Factor 3B Subunit 1, a core U2 small nuclear ribonucleoprotein component, thereby activating the spliceosome. Since splicing is closely linked to optimal transcription and cell proliferation, inhibition of CDK11 is hypothesized to indirectly disrupt general transcription and cell cycle progression. CDK11 drives cancer cell proliferation, promotes HIV-1 mRNA 3'-end processing to enhance viral replication, and contributes to tau phosphorylation in Alzheimer's disease. Given its integral role in key cellular processes and its dysregulation in various diseases, CDK11 has emerged as a compelling therapeutic target. This review provides a comprehensive overview of the biological functions and regulatory mechanisms of CDK11, discusses its role in cancer, viral and neurodegenerative diseases, and highlights advances in the discovery and development of CDK11 inhibitors, including OTS964, which has expanded our understanding of the biological functions of CDK11 and its prospects as a cancer-specific vulnerability.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500305"},"PeriodicalIF":3.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma. 靶向胶质母细胞瘤的新型抗癌吡唑嘧啶类药物的研究进展。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-08 DOI: 10.1002/cmdc.202500337

Kate Byrne, Natalia Bednarz, Ciara McEvoy, John C Stephens, James F Curtin, Gemma Kinsella

{"title":"Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma.","authors":"Kate Byrne, Natalia Bednarz, Ciara McEvoy, John C Stephens, James F Curtin, Gemma Kinsella","doi":"10.1002/cmdc.202500337","DOIUrl":"https://doi.org/10.1002/cmdc.202500337","url":null,"abstract":"Glioblastoma (GBM) is the most common and aggressive malignant grade IV brain tumour and is one of the most difficult types of brain cancer to treat with a high incidence of resistance to traditionally used chemotherapeutics. Pyrazolopyrimidinones are fused nitrogen-containing heterocyclic systems which are a scaffold in several bioactive drugs and drug candidates. Here, a structure activity relationship (SAR) study was performed where 23 substituted pyrazolo[1,5-α]pyrimidinones were screened for cytotoxicity against the GBM U-251 MG cell line and the non-cancerous embryonic kidney HEK293 cell line to assess their potential as anti-glioblastoma agents capable of selectivity for cancer cells. Through analogue synthesis of preliminary HIT compounds with varied structural substituents, a lead compound, 22, has been identified, which proved capable of inducing significant GBM cell death while having a marginal cytotoxicity against the non-cancerous cells. The mode of cell death studies suggested that the structurally varied HIT compounds induced cell death through differential mechanisms including cell membrane permeabilization and mitochondria membrane depolarization dependent mechanisms such as necrosis or apoptosis. The results highlight the potential of pyrazolo[1,5-α]pyrimidinones derivatives as a novel anti-glioblastoma therapy, capable of selectively killing cancer cells. Furthermore pyrazolo[1,5-α]pyrimidinones provide a scaffold for further development of selective glioblastoma therapies.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500337"},"PeriodicalIF":3.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adamantane Appended 1,2,3-Triazole Hybrids: Synthesis and α-Glucosidase Inhibition Studies Through Experimental and In Silico Approach. 金刚烷附加1,2,3-三唑杂化物的合成及α-葡萄糖苷酶抑制实验研究。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-08 DOI: 10.1002/cmdc.202500263

Aman Ragshaniya, Subhadip Maity, Lokesh Kumar, Vivek Asati, Poojita Poojita, Avijit Kumar Paul, Jayant Sindhu, Kashmiri Lal

{"title":"Adamantane Appended 1,2,3-Triazole Hybrids: Synthesis and α-Glucosidase Inhibition Studies Through Experimental and In Silico Approach.","authors":"Aman Ragshaniya, Subhadip Maity, Lokesh Kumar, Vivek Asati, Poojita Poojita, Avijit Kumar Paul, Jayant Sindhu, Kashmiri Lal","doi":"10.1002/cmdc.202500263","DOIUrl":"https://doi.org/10.1002/cmdc.202500263","url":null,"abstract":"In search of potent inhibitors of α-glucosidase, we have synthesized amide coupled adamantane derived 1,2,3-triazoles (4a-4f, 6a-6f, and 8a-8f) using Click reaction. After establishing their structure using spectral studies, all the molecular hybrids were assayed for α-glucosidase inhibition assay. Compounds 6c (IC50 = 8.30 ± 0.33 μM) and 6b (IC50 = 14.0 ± 0.16 μM) demonstrated promising inhibition of α-glucosidase in comparison to reference used (Acarbose, IC50 = 13.50 ± 0.32 μM). The role of various covalent linkers between triazole and phenyl ring has been established using structure activity relationship (SAR). The most probable mode of inhibition was studied by docking the most active compound 6c and Acarbose within the protein target (PDB ID: 3L4U). Further, 100 ns dynamics simulations were conducted to gain a detailed understanding of the complex stability. Binding energy for both the simulated complexes was calculated using MMGBSA and MMPBSA analysis, where compound 6c and Acarbose demonstrates a ΔGbind of -15.74 kcal/mol, and -46.37 kcal/mol. All compounds fit in the Lipinski rules of five, when ADME studies was carried out. This study paves the way for developing small molecule based α-glucosidase inhibitors as potential lead molecules using these frameworks.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500263"},"PeriodicalIF":3.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3'-Dehydroxypurpurogallin-4-Carboxamides as Influenza A Endonuclease Inhibitors: Synthesis, Structure-Activity Relationship Analysis, and Structural Characterization of Protein Complex. 3'-去羟基嘌呤没食子素-4-羧酰胺作为甲型流感核酸内切酶抑制剂：合成、构效关系分析和蛋白质复合物的结构表征。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-03 DOI: 10.1002/cmdc.202500452

Michal Kráľ, Tomáš Kotačka, Róbert Reiberger, Gabriela Panýrková, Kateřina Radilová, Zuzana Osifová, Miroslav Flieger, Jan Konvalinka, Pavel Majer, Milan Kožíšek, Aleš Machara

引用次数: 0

Front Cover: (ChemMedChem 13/2025) 封面：（ChemMedChem 13/2025）

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-02 DOI: 10.1002/cmdc.202581301

引用次数: 0

NSAIDS AS MODULATORS OF CATION CHANNELS: FENAMATES REPURPOSING IN CHANNELOPATHIES. 非甾体抗炎药作为阳离子通道调节剂：通道病变中的雌性动物再利用。

IF 3.6 4区医学

ChemMedChem Pub Date : 2025-07-02 DOI: 10.1002/cmdc.202500301

Paola Laghetti, Concetta Altamura, Simone Dell'Atti, Jean-François Desaphy, Ilaria Saltarella

{"title":"NSAIDS AS MODULATORS OF CATION CHANNELS: FENAMATES REPURPOSING IN CHANNELOPATHIES.","authors":"Paola Laghetti, Concetta Altamura, Simone Dell'Atti, Jean-François Desaphy, Ilaria Saltarella","doi":"10.1002/cmdc.202500301","DOIUrl":"https://doi.org/10.1002/cmdc.202500301","url":null,"abstract":"Cationic ion channels are transmembrane proteins that regulate the flux of cations (potassium, sodium, and calcium) across cell membrane, playing a pivotal role in many cellular functions. Disruptions of their activity can lead to the so-called genetic or acquired channelopathies, a heterogeneous group of diseases that affect multiple human systems. Fenamates, a class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), has recently emerged as modulators of cationic ion channels highlighting the possibility of their repurposing for the treatment ion channel-related disorders, such as channelopathies, chronic pain, epilepsy, cardiac arrhythmias and cancers. In this review, we describe the ability of fenamates (i.e. niflumic, flufenamic, mefenamic, meclofenamic and tolfenamic acids) to differentially modulate the activity of cationic ion channels. Overall, preclinical and clinical studies suggest that fenamates represent a promising class of compounds for drug repurposing and for the development of new molecules, offering novel therapeutic opportunities for patients affected by ion channel-related disorders.","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500301"},"PeriodicalIF":3.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ChemMedChem最新文献